Epinephrine Shortage Update: What Patients Need to Know in 2026

If you've been following the epinephrine auto-injector shortage since its peak in 2018–2019, you may be wondering: has anything changed? The short answer is yes — but not completely. Here is the most current update on epinephrine availability for patients in 2026.

Current Status: Is Epinephrine in Shortage in 2026?

As of 2026, epinephrine auto-injectors are generally available in the United States, but intermittent regional shortages continue. The worst of the crisis — the 2018–2019 nationwide shortage when patients in many areas couldn't find any auto-injectors at all — has not returned. However, patients in certain regions or those looking for specific products (particularly EpiPen Jr 0.15 mg) may still experience difficulty filling their prescriptions.

The ASHP drug shortage database continues to track certain epinephrine injection formulations (particularly the hospital-use prefilled syringes), and the auto-injector market remains constrained enough that stock varies significantly from pharmacy to pharmacy.

What Happened: A Brief Shortage Timeline

2017–2018: Manufacturing problems at Meridian Medical Technologies, the Pfizer subsidiary that makes EpiPen devices, triggered the first significant shortage.

2018–2019: The shortage reached its worst point. The FDA extended expiration dates on certain EpiPen lots by four months as an emergency measure.

2018: The FDA approved the first generic version of EpiPen from Teva Pharmaceuticals, adding competition.

2020–2023: Gradual supply improvement as manufacturing corrected and more generics entered the market. Seasonal shortages persisted.

August 2024: FDA approved neffy, the first needle-free nasal spray epinephrine product, expanding patient options further.

2025–2026: Multiple products on market (EpiPen, authorized generic, Auvi-Q, Adrenaclick, Symjepi, neffy). Spot shortages and regional variability continue, particularly during back-to-school season.

Why Do Shortages Keep Coming Back?

Several structural factors keep epinephrine auto-injectors vulnerable to supply disruptions even years after the initial crisis:

Few manufacturers: Despite the introduction of generics, only a handful of companies manufacture epinephrine auto-injectors in the U.S. A problem at any single manufacturer ripples across the entire market.

Short shelf life: Auto-injectors expire within 12–18 months. This creates constant demand for fresh production runs and leaves little buffer if output slows.

Seasonal demand spikes: The back-to-school rush in August–September predictably overwhelms pharmacy inventory every year.

Complex device manufacturing: Auto-injectors combine a drug with a precision mechanical device. Quality issues in either component can halt production without warning.

Which Epinephrine Products Are Available in 2026?

Patients in 2026 have more options than at any previous point:

EpiPen / EpiPen Jr (Viatris): 0.3 mg and 0.15 mg; most recognized brand

Authorized generic (Viatris): Same device as EpiPen at lower cost

Auvi-Q (Kaléo): 0.1 mg, 0.15 mg, and 0.3 mg; compact talking auto-injector; $0 copay for commercially insured

Adrenaclick / generic (Amneal): 0.15 mg and 0.3 mg; often most affordable auto-injector option

Symjepi (Adamis): 0.15 mg and 0.3 mg prefilled syringe

neffy (ARS Pharma): Epinephrine nasal spray; approved August 2024; needle-free option

What Should Patients Do Right Now?

Given the ongoing variability in epinephrine availability, here are the most important steps for patients in 2026:

Refill early. Don't wait until your auto-injectors are expired or nearly expired. Start looking for refills 60 days before expiration.

Know your alternatives. If your usual product isn't available, Auvi-Q, Adrenaclick, Symjepi, or neffy may be in stock. Ask your doctor for a device-flexible prescription.

Use medfinder. [@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop calls pharmacies near you to find which ones can fill your epinephrine prescription — saving you time and reducing stress.

Talk to your allergist. If you've had difficulty filling your prescription repeatedly, discuss it at your next appointment. Allergists often know which products are currently easiest to find locally.

The Bottom Line for 2026

The epinephrine story in 2026 is one of slow but real improvement — more products, more generics, and generally better availability than the crisis years. But for individual patients who hit a stockout at the wrong time, the situation can still feel urgent. The best strategy is to stay proactive: know your alternatives and use tools like medfinder to find in-stock pharmacies near you.

To understand the deeper causes of the shortage, read our post on why epinephrine is so hard to find in 2026.